SCHEMBL4629264

SCHEMBL4629264

NC(=NC(=O)c1cc(Cl)ccc1Cl)N1CCc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.58
SMN1; SMN2 Q16637 5/20 0.50
MAPT P10636 4/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SPR P35270 1/20 0.47
CDK4 P11802 1/20 0.47
CCND1 P24385 1/20 0.47
LMNA P02545 2/20 0.47
TDP1 Q9NUW8 1/20 0.45
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 1/20 0.44
NOTUM Q6P988 1/20 0.44
AVPR1A P37288 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658155 0.88 SCN2A (0.62) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4628733 0.83 SCN2A (0.77) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4628750 0.82 SCN2A (0.69) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4656775 0.82 SCN2A (0.59) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4659179 0.81 SCN2A (0.62) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL6775304 0.78 MAPT (0.54) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4627586 0.76 SCN2A (0.67) SCN2ASMN1; SMN2MAPTTP53KMT2A
SCHEMBL4627492 0.76 SCN2A (0.60) SCN2ASMN1; SMN2SPRLMNATSHR
SCHEMBL7103365 0.76 MAPT (0.54) SCN2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4629261 0.75 SMN1; SMN2 (0.51) SMN1; SMN2MAPTNPC1RAB9ASPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885SMN1; SMN2 53/4885MAPT 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.